Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors

PURPOSE: MK-2206 is an oral, highly selective inhibitor of AKT. The safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of MK-2206 was evaluated in Japanese patients with advanced solid tumors. METHODS: Patients received a single oral dose of MK-2206 according to an every other day...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Chemother Pharmacol
Asıl Yazarlar: Doi, Toshihiko, Tamura, Kenji, Tanabe, Yuko, Yonemori, Kan, Yoshino, Takayuki, Fuse, Nozomu, Kodaira, Makoto, Bando, Hideaki, Noguchi, Kazuo, Shimamoto, Takashi, Ohtsu, Atsushi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Berlin Heidelberg 2015
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4515243/
https://ncbi.nlm.nih.gov/pubmed/26104654
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-015-2810-z
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller